Rejenevie Therapeutics

Rejenevie Therapeutics is a private clinical-stage biotechnology company focused on immune restoration and therapies for aging-related disease. The company's lead program, AR-100, is an autologous mobilized peripheral blood cell therapy designed to restore function in the aging hematopoietic and immune systems using a proprietary mixed-age cell culture approach. Rejenevie positions its strategy around treating the biological drivers of aging rather than individual late-stage diseases alone. Its clinical work has been associated with treatment delivery at the Okyanos Center for Regenerative Medicine in Freeport, Bahamas, under Bahamian oversight. The company also describes a second-generation effort involving selected microRNAs for future treatment of age-related disease, cancer, and infectious disease.